Carl Hansen
Co-Founder, President & CEO
microfluidicssingle-cell biologyAI-driven drug discovery
Details
- ●Modalities: monoclonal antibodies, bispecific antibodies, antibody discovery platform
- ●Therapeutic areas: women's health, immunology, inflammation, oncology
- ●Key targets: NKp46 receptor (ABCL635), OX40L (ABCL575), undisclosed targets (20+ programs)
- ●Indications: vasomotor symptoms (hot flashes), atopic dermatitis, inflammatory and autoimmune conditions
- ●Funding: ~$600M IPO (2020) + $1.5B non-dilutive partner funding
Partners & investors
- Public (NASDAQ: ABCL)· Investor
- OrbiMed· Investor
- DCVC Bio· Investor
- Peter Thiel / Founders Fund· Investor
- Eli Lilly (partner)· Investor
Key considerations
- ●AI tools in use: Proprietary single-cell antibody screening platform, ML-driven antibody sequence optimization, High-throughput microfluidics + computational biology, Trianni transgenic mouse platform
- ●AI/ML core to antibody discovery: screens millions of B cells per campaign
- ●100+ pharma/biotech partners have used the platform
- ●Discovered bamlanivimab (COVID-19 antibody) in under 3 weeks for Eli Lilly
Pipeline
- Phase 11
- Phase 21
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)
Key people
Ester Falconer
Chief Technology Officer
antibody engineeringhigh-throughput screeningcomputational biology